T Fukushima

Summary

Affiliation: Kanazawa Medical University
Country: Japan

Publications

  1. ncbi request reprint Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib
    Toshihiro Fukushima
    Department of Hematology and Immunology, Kanazawa Medical University, 1 1 Daigaku, Uchinada, Ishikawa 920 0293, Japan
    Anticancer Res 32:5437-40. 2012
  2. ncbi request reprint Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline
    Toshihiro Fukushima
    Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan
    Anticancer Res 32:1347-53. 2012
  3. ncbi request reprint A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia
    Toshihiro Fukushima
    Department of Hematology and Immunology, Kanazawa Medical University, 1 1 Daigaku, Uchinada, Ishikawa 920 0293, Japan
    Anticancer Res 32:643-7. 2012
  4. ncbi request reprint Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events
    Toshihiro Fukushima
    Department of Hematology and Immunology, Kanazawa Medical University, 1 1 Daigaku, Uchinada, Ishikawa 920 0293, Japan
    Anticancer Res 31:2297-302. 2011
  5. ncbi request reprint Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia
    Toshihiro Fukushima
    Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan
    Anticancer Res 31:1741-4. 2011
  6. ncbi request reprint Complete response obtained by bortezomib plus dexamethasone in a patient with relapsed multiple myeloma with multiple plasmacytomas
    Toshihiro Fukushima
    Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan
    Anticancer Res 30:3791-4. 2010
  7. ncbi request reprint MRSA-pyomyositis in a patient with acute myelogenous leukemia after intensive chemotherapy
    Toshihiro Fukushima
    Department of Hematology and Immunology, Kanazawa Medical University, 1 1 Daigaku, Uchinada, Ishikawa 920 0293, Japan
    Anticancer Res 29:3361-4. 2009
  8. doi request reprint Successful treatment of amegakaryocytic thrombocytopenia with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus
    T Fukushima
    Division of Hematology and Immunology, Department of Internal Medicine, Kanazawa Medical University, Kahoku gun, Ishikawa, Japan
    Lupus 17:210-4. 2008
  9. doi request reprint Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders
    Y Masaki
    Department of Hematology and Immunology, Kanazawa Medical University, 1 1 Daigaku, Uchinada, Kahoku gun, Ishikawa, 920 0293, Japan
    Ann Rheum Dis 68:1310-5. 2009
  10. pmc Clonality analysis of lymphoproliferative disorders in patients with Sjögren's syndrome
    L Dong
    Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan
    Clin Exp Immunol 150:279-84. 2007

Collaborators

Detail Information

Publications10

  1. ncbi request reprint Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib
    Toshihiro Fukushima
    Department of Hematology and Immunology, Kanazawa Medical University, 1 1 Daigaku, Uchinada, Ishikawa 920 0293, Japan
    Anticancer Res 32:5437-40. 2012
    ..There are some reports that acyclovir reduces the risk of VZV reactivation. We assessed whether VZV reactivation could be reduced by using prophylactic valacyclovir at a dose of 500 mg daily...
  2. ncbi request reprint Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline
    Toshihiro Fukushima
    Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan
    Anticancer Res 32:1347-53. 2012
    ....
  3. ncbi request reprint A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia
    Toshihiro Fukushima
    Department of Hematology and Immunology, Kanazawa Medical University, 1 1 Daigaku, Uchinada, Ishikawa 920 0293, Japan
    Anticancer Res 32:643-7. 2012
    ..0 g/m(2) every 12 hours for 5 days) in post-remission therapy for acute myeloid leukemia (AML) to confirm the post-remission antileukemic efficacy and safety of mIDAC...
  4. ncbi request reprint Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events
    Toshihiro Fukushima
    Department of Hematology and Immunology, Kanazawa Medical University, 1 1 Daigaku, Uchinada, Ishikawa 920 0293, Japan
    Anticancer Res 31:2297-302. 2011
    ..To establish the clinical use of bortezomib with fewer adverse events, we retrospectively analyzed the efficacy and safety of bortezomib plus dexamethasone (BD) therapy for relapsed or refractory multiple myeloma...
  5. ncbi request reprint Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia
    Toshihiro Fukushima
    Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan
    Anticancer Res 31:1741-4. 2011
    ..Four months after discontinuation of deferasirox, the blood cell count normalized and the patient became transfusion-independent. Bone marrow aspiration and biopsy revealed hematological and cytogenetic CR...
  6. ncbi request reprint Complete response obtained by bortezomib plus dexamethasone in a patient with relapsed multiple myeloma with multiple plasmacytomas
    Toshihiro Fukushima
    Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan
    Anticancer Res 30:3791-4. 2010
    ..CONCLUSION: This case report indicates that bortezomib may be a promising agent for MM with multiple plasmacytomas...
  7. ncbi request reprint MRSA-pyomyositis in a patient with acute myelogenous leukemia after intensive chemotherapy
    Toshihiro Fukushima
    Department of Hematology and Immunology, Kanazawa Medical University, 1 1 Daigaku, Uchinada, Ishikawa 920 0293, Japan
    Anticancer Res 29:3361-4. 2009
    ..CONCLUSION: If an immunocompromised patient complains of fever and muscle pain after intensive chemotherapy, MRSA-pyomyositis should be considered...
  8. doi request reprint Successful treatment of amegakaryocytic thrombocytopenia with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus
    T Fukushima
    Division of Hematology and Immunology, Department of Internal Medicine, Kanazawa Medical University, Kahoku gun, Ishikawa, Japan
    Lupus 17:210-4. 2008
    ....
  9. doi request reprint Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders
    Y Masaki
    Department of Hematology and Immunology, Kanazawa Medical University, 1 1 Daigaku, Uchinada, Kahoku gun, Ishikawa, 920 0293, Japan
    Ann Rheum Dis 68:1310-5. 2009
    ..Mikulicz's disease (MD) has been considered as one manifestation of Sjögren's syndrome (SS). Recently, it has also been considered as an IgG(4)-related disorder...
  10. pmc Clonality analysis of lymphoproliferative disorders in patients with Sjögren's syndrome
    L Dong
    Department of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan
    Clin Exp Immunol 150:279-84. 2007
    ....